Cellular abundance of es nucleoside transporters and differential drug toxicity in myelodysplastic syndrome (MDS) bone marrow cell subpopulations.
Gati
W P
WP
Departments of Pharmacology, Oncology, University of Alberta, Cross Cancer Institute, 9-70 Medical Sciences Building, Edmonton, Alberta, Canada, T6G 2H7.
Larratt
L M
LM
Turner
A R
AR
D000241:Adenosine / Q000031:analogs & derivatives*; D000964:Antimetabolites, Antineoplastic / Q000633:toxicity; D000970:Antineoplastic Agents / Q000633:toxicity*; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism*; D002352:Carrier Proteins / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects; D003561:Cytarabine / Q000633:toxicity; D005434:Flow Cytometry; D005456:Fluorescent Dyes; D006801:Humans; D008024:Ligands; D008565:Membrane Proteins / Q000378:metabolism*; D008727:Methotrexate / Q000633:toxicity; D009190:Myelodysplastic Syndromes / Q000378:metabolism* / Q000473:pathology; D033703:Nucleoside Transport Proteins; D013872:Thionucleosides
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D005456:Fluorescent Dyes; D008024:Ligands; D008565:Membrane Proteins; D033703:Nucleoside Transport Proteins; D013872:Thionucleosides; D003561:Cytarabine; C066257:5'-S-(2-aminoethyl)-N(6)-(4-nitrobenzyl)-5'-thioadenosine; D000241:Adenosine; D008727:Methotrexate